eviously were incubated in caspase cleavage buffer with recombinant caspases for 90 min at 30 C as described previously. cDNAs encoding individual caspases were a gift of H. Li and J. Yuan. The data for caspase-8 cleavage of SRPK1 was confirmed using recombinant, purified His-tagged caspase-8. Recombinant caspases were prepared as described and frozen at 80 C until used. In a separate reaction, the mixture was then separated by SDS-PAGE, transferred to nitrocellulose and exposed for autoradiography. In separate experiments, each caspase was incubated with in vitrotranslated proteins including p35, procaspase 2, or IL-1 to confirm their activity. 1214 Identification of an Autoantigen Kinase Signaling Pathway Immunoprecipitation and Western Blot Analysis. Lysates were precleared once with 100 l of a 50% solution of protein A-Sepharose in detergent lysis buffer and 5 g rabbit antimouse IgG for 12 h. Mouse mAbs were used as follows: anti-SRPK1 and anti-SRPK2; anti-cdc2; anti-SC35; and anti-U2B . Human autoimmune serum samples were employed as follows: 3 l human polyclonal antiScl-70 or antiU1-snRNP. U1-snRNP-specific sera that were previously shown to coprecipitate SR proteins and control sera have been described previously. 2 l antiDNA-dependent protein kinase was used for IP kinase and Western blotting experiments. Immunoprecipitations were performed after addition of detergent lysis buffer to a total volume of 500 l, and rotation in a 4 C cold room for 24 h. Precipitates were harvested by centrifuging for 20 s at 12,000 rpm in a refrigerated Heraeus microfuge, washing three times with detergent lysis buffer, resuspending in SDS loading buffer with 9% 2-mercaptoethanol, boiling for 5 min, and separating by SDS-PAGE as described previously. Proteins were transferred to PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/19804394 nitrocellulose for Western blotting experiments. Antibodies and dilutions used were as follows: anti-cdc2 ; antiDNA-PKCS; anti-SRPKs; anti-topoisomerase I is a synthetic compound that promotes the activity of pyruvate dehydrogenase by inhibiting its repressor protein called pyruvate dehydrogenase kinase. The activation of PDH leads to a reduction in ambient cellular lactate concentrations both in vitro and in vivo which contributes to the therapeutic use of DCA in the treatment of systemic lactic acidosis in humans. The therapeutic potential of DCA is now being explored in disorders that are accompanied by elevations of lactate concentration such as in hypoxic cancer cells. Yet conflicting evidence regarding its mutagenic potential has been a major setback in its clinical trials. Hence, docking and descriptor PD-1/PD-L1 inhibitor 2 analysis of halogen substituted DCA analogues were performed to find out a drug candidate with less toxicity and better binding affinity than DCA. The Docking analysis was carried out using human PDHK isozyme 2, the physiological receptor for DCA. Bromoacetate and Diiodoacetate were found out to be the plausible analogues of DCA from this study. Keywords: PDH, PDHK, DCA, Docking and descriptor analysis. Abbreviations: DCA = Dichloroacetate, PDH = Pyruvate dehydrogenase, PDHK = Pyruvate dehydrogenase kinase. Background: Cancer development and its confrontation to chemotherapy depend, at least in part, on suppression of apoptosis. Although mitochondria are recognized as regulators of apoptosis, their importance as targets for cancer therapy has not been adequately explored or clinically exploited. Studies suggest that mitochondrial dysfunction in cancer cells may result i